Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Animal or plant cell
Reexamination Certificate
2005-03-22
2005-03-22
Naff, David M. (Department: 1651)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Animal or plant cell
C424S093400, C424S093700, C435S002000
Reexamination Certificate
active
06869602
ABSTRACT:
Disclosed herein are RBC preparations and methods of making and using thereof for treating, preventing or inhibiting ETEC infections. In particular, bovine red blood cell (RBC) preparations are shown to reduce enterotoxigenicEscherichia coli(ETEC) adhesion when administered orally. Also disclosed are kits comprising RBC preparations for the treatment of ETEC infections.
REFERENCES:
patent: 4971794 (1990-11-01), Linggood et al.
patent: 5017372 (1991-05-01), Hastings
patent: 5891860 (1999-04-01), Heerze et al.
patent: 1124976 (1984-11-01), None
C. Ahren et al., (1993) “Intestinal antibody response after oral immunization with a prototype cholera B subunit-colonization factor antigen enterotoxigenicEscherichia colivaccine” Vaccine, vol. 11, (9); 929-934.
F.J. Cassels et al., (1995) “Colonization factors of diarrheagenicE. coliand their intestinal receptors” J. Ind. Microbiol., vol. 15 (3): 214-226.
Dodge et al., (1963) “The Preparation and Chemical Characteristics of Hemoglobin-Free Ghosts of Human Erythrocytes” Arch. Biochem. Biophys., vol. 100, pp. 119-130.
M. Jertborn et al., (1998) “Safety and immunogenicity of an oral inactivated enterotoxigenicEscherichia colivaccine” Vaccine, vol. 16 (2/3):255-260.
H. Ryu et al., (2001) “Escherichia coliStrain RDEC-1 AF/R1 Endogenous Fimbrial Glycoconjugate Receptor Molecules in Rabbit Small Intestine” Infect. Immun., vol. 69(2): 640-649.
M.K. Wolf et al., (1993) “Characterization of EnterotoxigenicEscherichia coliIsolated from U.S. Troops Deployed to the Middle East” J. Clin. Microbiol., vol. 31(4): 851-856.
F.K. De Graaf et al., “The Fimbrial Adhesins ofEscherichia coli”, pp. 65-143.
M. Jertborn et al., Vaccine, vol. 16, (1988), pp. 255-260.
Karl-Anders Karlsson, “Animal Glycosphingolipids as Membrane Attachment Sites for Bacteria”, Annu. Rev. Biochem.. vol. 58, (1989), pp. 309-350.
Sami B. Khalil et al., “Characterization of an EnterotoxigenicEscherichia ColiStrain from Africa Expressing a Putative Colonization Factor”, Infection and Immunity, vol. 67, No. 8, (1999), pp. 4019-4026.
Stuart Knutton et al., “Ultrastructural Study of Adhesion of EnterotoxigenicEscherichia Colito Erythrocytes and Human Intestinal Epithelial Cells”, Infection and Immunity, vol. 44, No. 2, (1984), pp. 519-527.
Myron M. Levine et al., “Lack of Person-To-Person Transmission of EnterotoxigenicEscherichia ColiDespite Close Contact”, American Journal of Epidemiology, vol. 111, No. 3, pp. 347-355.
Myron M. Levine et al., “Immunity to EnterotoxigenicEscherichia Coli”, Infection and Immunity, vol. 23, No. 3, (1979), pp. 729-736.
M. M. Levine et al., “Reactogencity, Immunogenicity and Efficacy Studies ofEscherichia ColiType 1 Somatic Pili Parenteral Vaccine in Man”, Scand J. Infect. Dis. Suppl. vol. 33, (1982), pp. 83-95.
John L. Magnani et al., “A Monoclonal Antibody-Defined Antigen Associated with Gastrointestinal Cancer is a Ganglioside Containing Sialylated Lacto-N-Fucopentaose II”, The Journal of Biological Chemistry, vol. 257, No. 23, (1982), pp. 14365-14369.
Heikki Peltola et al., “Prevention of Travellers' Diarrhoea by Oral B-Subunit/Whole-Celll Cholera Vaccine”, The Lancet, vol. 338, (1991), pp. 1285-1289.
H. Ryu et al., Infect. Immun., vol. 69, (2001), pp. 640-649.
Barbara J. Stoll et al., “Local and Systemic Antibody Responses to Naturally Acquired EnterotoxigenicEscherichia ColiDiarrhea in an Endemic Area”, The Journal of Infectious Diseases, vol. 153, No. 3, (1986), pp. 527-534.
Ann-Mari Svennerholm, “Serologic Differentiation Between Antitoxin Responses to Infection with Vibrio Cholerae and Enterotoxin-ProducingEscherichia Coli”, The Journal of Infectious Diseases, vol. 147, No. 3, (1983), pp. 514-522.
Carol O. Tacket et al., “Protection By Milk Immunoglobulin Concentrate Against Oral Challenge with EnterotoxigenicEscherichia Coli”, The New England Journal of Medicine, vol. 318, No. 19, (1988), pp. 1240-1243.
M.K. Wolf et al., Clin. Microbiol., vol. 31, (1993), pp. 851-856.
C. Ahren et al., Vaccine, vol. 11, (1993), pp. 929-934.
Edwin H. Beachey, “Bacterial Adherence: Adhesin-Receptor Interactions Mediating the Attachment of Bacteria to Mucosal Surfaces”, The Journal of Infectious Diseases, vol. 143, No. 3, (1981), pp. 325-345.
August L. Bourgeois et al., “Etiology of Acute Diarrhea Among United States Military Personnel Deployed to South America and West Africa”, Am. J. Trop. Med. Hgy., vol. 48, No. 2, (1993), pp. 243-248.
F.J. Cassels et al., J. Ind. Microbiol., vol. 15, (1995), pp. 214-226.
Christopher P. Cheney et al., “Quantitation of the Adherence of an EnteropathogenicEscherichia Colito Isolated Rabbit Intestinal Brush Borders”, Infection and Immunity, vol. 26, No. 2, (1979), pp. 736-743.
Trinka S. Coster et al., “Safety, Immunogenicity, and Efficacy of Live AttenuatedVibrio Cholerae0.139 Vaccine Prototype”, The Lancet, vol. 345, (1995), pp. 949-952.
Dodge et al., Arch. Biochem. Biophys., vol. 201, (1962), pp. 119-130.
Charles D. Ericsson et al., “Travelers' Diarrhea: Approaches to Prevention and Treatment”, Clinical Infectious Diseases, vol. 16, (1993), pp. 616-626.
Doyle J.Evans et al., “Hemagglutination Patterns of Enterotoxigenic and EnteropathogenicEscherichia ColiDetermined with Human, Bovine, Chicken, and Guinea Pig Erythcrocytes in the Presence and Absence of Mannose”, Infection and Immunity, vol. 23, No. 2, (1979), pp. 336-346.
Janina Goldhar, “[4] Erythrocytes as target Cells for Testing Bacterial Adhesins”, Methods in Enzymology, vol. 253, pp. 43-50.
Enrique A. Gonzalez et al., “Comparative Study of Inhibition of Mannose-Resistant Haemagglutination Caused by CFA/I, CFA/II, K88 and K99-positiveEscherichia ColiStrains”, FEMS Microbiology Letters, vol. 29, (1985), pp. 115-121.
Cassels Frederick J.
Ryu Hyoik
Arwine Elizabeth
Naff David M.
The United States of America as represented by the Secretary of
Ware Deborah K.
LandOfFree
Method for treating, preventing, or inhibiting... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating, preventing, or inhibiting..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating, preventing, or inhibiting... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3451839